Skip to main content

Table 1 Clinical characteristics of the Nordic JIA study population

From: Fatigue in young adults with juvenile idiopathic arthritis 18 years after disease onset: data from the prospective Nordic JIA cohort

Characteristics Total no. assessed Values
Female sex, no. (%) 377 271 (72)
Age at disease onset, years, median (IQR) 377 5.6 (2.6–9.7)
Age at 18-year follow-up, years, median (IQR) 377 23.3 (20.2–27.1)
Disease duration at 18-year follow-up, years, median (IQR) 375 17.5 (16.8–18.3)
Oligoarticular JIA at onset, no. (%) 377 201 (53)
Oligoarticulara JIA at 18-year follow-up, no. (%) 377 175 (46)
VAS pain at 18-year follow-up, mean (±SD) 370 1.9 (±2.4)
SF-36 PCS at 18-year follow-up, mean (±SD) 377 51.5 (±9.7)
SF-36 MCS at 18-year follow-up, mean (±SD) 377 49.1 (±11.3)
HAQ at 18-year follow-up, mean (±SD) 370 0.2 (±0.4)
Not in remissionb at 18-year follow-up (visits), no. (%) 308 196 (63)
Not in remissionb at 18-year follow-up (visits/telephonec), no. (%) 369 215 (58)
DMARDs and/or biologics ongoing at 18-year follow-up, no. (%) 377 118 (31)
DMARDs and/or biologics ever during disease course, no. (%) 377 239 (63)
  1. JIA juvenile idiopathic arthritis, no. numbers, IQR interquartile range, 1st-3rd, SD standard deviation, VAS pain self-reported pain measured on a 21-numbered circle visual analogue scale (0 = no pain, 10 = maximum pain), SF-36 Short-form 36 Health Status Questionnaire, 0–100 (< 40 poor health), PCS physical component summary, MCS mental component summary, HAQ Health Assessment Questionnaire, 0–3 (0 = lowest, 3 = highest), DMARDs disease-modifying anti-rheumatic drugs, biologics biologic drugs
  2. aPersistent (no. =98) and extended (no. =77) oligoarticular disease
  3. bNot in remission off medication according to the definition by Wallace et al.
  4. c61 participated only in a telephone interview